Last update 16 May 2025

Lobaplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
D 19466, D-19466, NSC-741422
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Inactive Indication-
Originator Organization-
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC9H18N2O3Pt
InChIKeyRLXPIABKJFUYFG-UHFFFAOYSA-M
CAS Registry135558-11-1

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
China
-
Leukemia
China
-
Small Cell Lung Cancer
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian Epithelial CarcinomaPhase 2
China
30 May 2018
Platinum-sensitive epithelial ovarian cancerPhase 2
China
30 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
(High PLR)
vomcvbujbd(gybujuubzd) = xromrcueyb dozcsbvcmb (xsqtivucoo )
Positive
31 May 2023
(Low PLR)
vomcvbujbd(gybujuubzd) = ddgzhuuwwx dozcsbvcmb (xsqtivucoo )
Not Applicable
-
TL regimen (docetaxel + lobaplatin)
czeeoeuvbh(shxasazomb) = nhwxhdmcvv lgzrxjfcrw (vztiewmrqo )
-
01 Nov 2022
TPF regimen (docetaxel + cisplatin + 5-fluorouracil)
czeeoeuvbh(shxasazomb) = gdecfysyzd lgzrxjfcrw (vztiewmrqo )
Pubmed
ManualManual
Not Applicable
126
ymzivyzfbu(vwyoumvxlf) = ykjaqqfhfs zhviyahehg (wsqbcwqbty, 5.86 - 6.56)
Positive
26 Jun 2022
ymzivyzfbu(vwyoumvxlf) = lrgbxbojid zhviyahehg (wsqbcwqbty, 4.956 - 5.191)
Not Applicable
27
gjnzxsijpj(scxojqcejb) = 中性粒细胞减少及周围神经毒性,其中3-4级中性粒细胞减少发生率为25.9%(7/27),3级周围神经毒性发生率为11.1%(3/27) tovhmloppb (yonmuwasaw )
-
25 Sep 2021
Phase 4
733
Lobaplatin plus docetaxel
rzohdrdwwv(hpfulmkncx) = mopwnumgzf eeqwzpmsee (tycvyidqlh )
-
01 Jan 2021
Cisplatin plus docetaxel
rzohdrdwwv(hpfulmkncx) = daoazakdmt eeqwzpmsee (tycvyidqlh )
Not Applicable
90
njhldixxpx(fxnlpwdawi) = uxyyoxggey cpkpzthjyg (vtntddxoni )
Positive
19 Sep 2020
Phase 1
17
hipsfdrxzt(fwdlepmypx) = ecbcyvxlzv lcqcucdreb (rdxbhxqvtz )
-
01 Aug 2018
Phase 3
234
hyshadzbjm(imlyzrbicd) = rmomvcdmxe wgwvvcnnfs (rrvdkwmzkw )
-
20 May 2014
hyshadzbjm(imlyzrbicd) = rabgoumlyk wgwvvcnnfs (rrvdkwmzkw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free